Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 17/20 | 0.78 |
| ▸ | DPP4 | P27487 | 11/20 | 0.78 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.78 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.78 |
| ▸ | FAP | Q12884 | 3/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2182868 | 1.00 | DPP7 (0.78) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL8852004 | 1.00 | DPP7 (0.78) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL7172842 | 0.84 | DPP4 (0.56) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL6826607 | 0.84 | DPP4 (1.00) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL1649751 | 0.83 | DPP4 (0.56) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL27920297 | 0.82 | DPP4 (0.53) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL145916 | 0.82 | DPP4 (0.63) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL10395663 | 0.81 | DPP4 (0.54) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL10395664 | 0.81 | DPP4 (0.54) | DPP7DPP4DPP8DPP9FAP | |
| Trifluoroacetic Acid SCHEMBL6824122 | 0.80 | DPP4 (0.84) | DPP7DPP4DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335645-B2 | Effectors of dipeptidyl peptidase IV for topical use | PROBIODRUG AG (DE) | 2008-02-26 | — | — | US | disclosed |
| US-6949515-B2 | Effectors of dipeptidyl peptidase IV for topical use | PROBIODRUG AG (DE) | 2005-09-27 | — | — | US | disclosed |
| US-20050209159-A1 | Effectors of dipeptidyl peptidase IV for topical use | PROBIODRUG AG (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20030092630-A2 | Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases | PROBIODRUG AG (DE) | 2003-05-15 | — | — | US | disclosed |
| US-20020165164-A1 | New effectors of dipeptidyl peptidase IV for topical use | DEMUTH HANS-ULRICH (DE) | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092630-A2 | Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases | DNPEP, PREP, ENPEP | DPP7 21/4885DPP4 26/4885DPP8 54/4885 |
| US-20020165164-A1 | New effectors of dipeptidyl peptidase IV for topical use | DNPEP, PREP, DPP4 | DPP7 9/4885DPP4 3/4885DPP8 17/4885 |
| US-20050209159-A1 | Effectors of dipeptidyl peptidase IV for topical use | DNPEP, PREP, DPP4 | DPP7 7/4885DPP4 3/4885DPP8 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.